Clinical importance of FANCD2, BRIP1, BRCA1, BRCA2 and FANCF expression in ovarian carcinomas

References

• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61(2):69–90. doi:10.3322/caac.20107.
   PubMed Web of Science ®Google Scholar
• McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334(1):1–6. doi:10.1056/NEJM199601043340101.
   PubMed Web of Science ®Google Scholar
• Piccart MJ, Du Bois A, Gore ME, Neijt JP, Pecorelli S, Pujade-Lauraine E. A new standard of care for treatment of ovarian cancer. Eur J Cancer. 2000;36(1):10–12. doi:10.1016/S0959-8049(99)00210-5.
   PubMed Web of Science ®Google Scholar
• Boulikas T, Pantos A, Bellis E, Christofis P. Designing platinum compounds in cancer: structures and mechanisms. Cancer Ther. 2007;5:537–583. doi:10.1016/j.jinorgbio.2014.07.011.
   Google Scholar
• Garcia-Higuera I, Taniguchi T, Ganesan S, Meyn MS, Timmers C, Hejna J, Grompe M, D’Andrea AD. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol Cell. 2001;7(2):249–262. doi:10.1016/S1097-2765(01)00173-3.
   PubMed Web of Science ®Google Scholar
• Niedzwiedz W, Mosedale G, Johnson M, Ong CY, Pace P, Patel KJ. The Fanconi anaemia gene FANCC promotes homologous recombination and error-prone DNA repair. Mol Cell. 2004;15(4):607–620. doi:10.1016/j.molcel.2004.08.009.
   PubMed Web of Science ®Google Scholar
• Cummings M, Higginbottom K, McGurk CJ, Wong OG, Köberle B, Oliver RT, Masters JR. XPA versus ERCC1 as chemosensitising agents to cisplatin and mitomycin C in prostate cancer cells: role of ERCC1 in homologous recombination repair. Biochem Pharmacol. 2006;72(2):166–175. doi:10.1016/j.bcp.2006.04.025.
   PubMed Web of Science ®Google Scholar
• Natarajan AT, Palitti F. DNA repair and chromosomal alterations. Mutat Res. 2008;657(1):3–7. doi:10.1016/j.mrgentox.2008.08.017.
   PubMed Web of Science ®Google Scholar
• Deans AJ, West SC. DNA interstrand crosslink repair and cancer. Nat Rev Cancer. 2011;11(7):467–480. doi:10.1038/nrc3088.
   PubMed Web of Science ®Google Scholar
• Furgason JM, Bahassi El M. Targeting DNA repair mechanisms in cancer. Pharmacol Ther. 2013;137(3):298–308. doi:10.1016/j.pharmthera.2012.10.009.
   PubMed Web of Science ®Google Scholar
• Konstantinopoulos PA, Ceccaldi R, Shapiro GI, D’Andrea AD. Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer. Cancer Discov. 2015;5(11):1137–1154. doi:10.1158/2159-8290.CD-15-0714.
   PubMed Web of Science ®Google Scholar
• Telli ML, Hellyer J, Audeh W, Jensen KC, Bose S, Timms KM, Gutin A, Abkevich V, Peterson RN, Neff C, et al. Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer. Breast Cancer Res Treat. 2018;168(3):625–630. DOI:10.1007/s10549-017-4624-7
   PubMed Web of Science ®Google Scholar
• Frey MK, Pothuri B. Homologous recombination deficiency (HRD) testing in ovarian cancer clinical practice: a review of the literature. Gynecol Oncol Res Pract. 2017;4:4. doi:10.1186/s40661-017-0039-8.
   PubMedGoogle Scholar
• De Picciotto N, Cacheux W, Roth A, Chappuis PO, Labidi-Galy SI. Ovarian cancer: status of homologous recombination pathway as a predictor of drug response. Crit Rev Oncol Hematol. 2016;101:50–59. doi:10.1016/j.critrevonc.2016.02.014.
   PubMed Web of Science ®Google Scholar
• Rossio V, Galati E, Piatti S. Adapt or die: how eukaryotic cells respond to prolonged activation of the spindle assembly checkpoint. Biochem Soc Trans. 2010;38(6):1645–1649. doi:10.1042/BST0381645.
   PubMedGoogle Scholar
• Seal S, Barfoot R, Jayatilake H, Smith P, Renwick A, Bascombe L, McGuffog L, Evans DG, Eccles D, Easton DF, et al. Evaluation of Fanconi Anemia genes in familial breast cancer predisposition. Cancer Res. 2003;63(24):8596–8599.
   PubMed Web of Science ®Google Scholar
• Nalepa G, Enzor R, Sun Z, Marchal C, Park SJ, Yang Y, Tedeschi L, Kelich S, Hanenberg H, Clapp DW. Fanconi anemia signaling network regulates the spindle assembly checkpoint. J Clin Invest. 2013;123(9):3839–3847. doi:10.1172/JCI67364.
   PubMed Web of Science ®Google Scholar
• Michl J, Zimmer J, Buffa FM, McDermott U, Tarsounas M. FANCD2 limits replication stress and genome instability in cells lacking BRCA2. Nat Struct Mol Biol. 2016;23(8):755–757. doi:10.1038/nsmb.3252.
   PubMed Web of Science ®Google Scholar
• Offman J, Gascoigne K, Bristow F, Macpherson P, Bignami M, Casorelli I, Leone G, Pagano L, Sica S, Halil O, et al. Repeated sequences in CASPASE-5 and FANCD2 but not NF1 are targets for mutation in microsatellite-unstable acute leukemia/myelodysplastic syndrome. Mol Cancer Res. 2005;3(5):251–260. doi:10.1158/1541-7786.MCR-04-0182.
   PubMed Web of Science ®Google Scholar
• Borriello A, Locasciulli A, Bianco AM, Criscuolo M, Conti V, Grammatico P, Cappellacci S, Zatterale A, Morgese F, Cucciolla V, et al. A novel Leu153Ser mutation of the Fanconi anemia FANCD2 gene is associated with severe chemotherapy toxicity in a pediatric T-cell acute lymphoblastic leukemia. Leukemia. 2007;21(1):72–78. doi:10.1038/sj.leu.2404468
   PubMed Web of Science ®Google Scholar
• Moes-Sosnowska J, Budzilowska A, Kupryjanczyk J. Mutation analysis of the FANCD2 gene in ovarian cancer patients from the Polish population. J Oncol. 2015;65(1):7–13. doi:10.5603/NJO.2015.0002.
   Google Scholar
• Rafnar T, Gudbjartsson DF, Sulem P, Jonasdottir A, Sigurdsson A, Jonasdottir A, Besenbacher S, Lundin P, Stacey SN, Gudmundsson J, et al. Mutations in BRIP1 confer high risk of ovarian cancer. Nat Genet. 2011;43(11):1104–1107. doi:10.1038/ng.955
   PubMed Web of Science ®Google Scholar
• Litman R, Peng M, Jin Z, Zhang F, Zhang J, Powell S, Andreassen PR, Cantor SB. BACH1 is critical for homologous recombination and appears to be the Fanconi anemia gene product FANCJ. Cancer Cell. 2005;8(3):255–265. doi:10.1016/j.ccr.2005.08.004.
   PubMed Web of Science ®Google Scholar
• Seal S, Thompson D, Renwick A, Elliott A, Kelly P, Barfoot R, Chagtai T, Jayatilake H, Ahmed M, Spanova K, et al. mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet. 2006;38(11):1239–1241. doi:10.1038/ng1902.
   PubMed Web of Science ®Google Scholar
• Ramus SJ, Song H, Dicks E, Tyrer JP, Rosenthal AN, Intermaggio MP, Fraser L, Gentry-Maharaj A, Hayward J, Philpott S, et al. Germline mutations in the BRIP1, BARD1, PALB2, and NBN genes in women with ovarian cancer. J Natl Cancer Inst. 2015;107(11):pii: djv214. DOI:10.1093/jnci/djv214
   PubMedGoogle Scholar
• Petrucelli N, Daly MB, Feldman GL. 2010. Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2. Genet Med. 12(5):245–259. doi:10.1097/GIM.0b013e3181d38f2f.
   PubMed Web of Science ®Google Scholar
• Stoppa-Lyonnet D. The biological effects and clinical implications of BRCA mutations: where do we go from here? Eur J Hum Genet. 2016;24(Suppl 1):S3–9. doi:10.1038/ejhg.2016.93.
   PubMedGoogle Scholar
• Godet I, Gilkes DM. BRCA1 and BRCA2 mutations and treatment strategies for breast cancer. Integr Cancer Sci Ther. 2017;4:1. doi:10.15761/ICST.1000228.
   Google Scholar
• Barroso E, Pita G, Arias JI, Menendez P, Zamora P, Blanco M, Benitez J, Ribas G. The Fanconi anemia family of genes and its correlation with breast cancer susceptibility and breast cancer features. Breast Cancer Res Treat. 2009;118(3):655–660. doi:10.1007/s10549-009-0439-5.
   PubMed Web of Science ®Google Scholar
• Narayan G, Arias-Pulido H, Nandula SV, Basso K, Sugirtharaj DD, Vargas H, Mansukhani M, Villella J, Meyer L, Schneider A, et al. Promoter hypermethylation of FANCF: disruption of Fanconi Anemia-BRCA pathway in cervical cancer. Cancer Res. 2004 May 1;64(9):2994–2997. doi:10.1158/0008-5472.CAN-04-0245.
   PubMed Web of Science ®Google Scholar
• Wang Z, Li M, Lu S, Zhang Y, Wang H. Promoter hypermethylation of FANCF plays an important role in the occurrence of ovarian cancer through disrupting Fanconi anemia-BRCA pathway. Cancer Biol Ther. 2006;5(3):256–260. doi:10.4161/cbt.5.3.2380.
   PubMed Web of Science ®Google Scholar
• Marsit CJ, Liu M, Nelson HH, Posner M, Suzuki M, Kelsey KT. Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival. Oncogene. 2004;23(4):1000–1004. doi:10.1038/sj.onc.1207256.
   PubMed Web of Science ®Google Scholar
• Tokunaga E, Okada S, Kitao H, Shiotani S, Saeki H, Endo K, Morita M, Kakeji Y, Maehara Y. Low incidence of methylation of the promoter region of the FANCF gene in Japanese primary breast cancer. Breast Cancer. 2011;18(2):120–123. doi:10.1007/s12282-009-0175-z.
   PubMed Web of Science ®Google Scholar
• Ziółkowska-Seta I, Madry R, Kraszewska E, Szymańska T, Timorek A, Rembiszewska A, Kupryjańczyk J. TP53, BCL-2 and BAX analysis in 199 ovarian cancer patients treated with taxane-platinum regimens. Gynecol Oncol. 2009;112(1):179–184. doi:10.1016/j.ygyno.2008.09.008.
   PubMed Web of Science ®Google Scholar
• Felisiak-Golabek A, Rembiszewska A, Rzepecka IK, Szafron L, Madry R, Murawska M, Napiorkowski T, Sobiczewski P, Osuch B, Kupryjanczyk J. Nuclear survivin expression is a positive prognostic factor in taxane-platinum-treated ovarian cancer patients. J Ovarian Res. 2011 Nov 10;4(1):20. doi:10.1186/1757-2215-4-20.
   PubMedGoogle Scholar
• Szafron LM, Balcerak A, Grzybowska EA, Pienkowska-Grela B, Podgorska A, Zub R, Olbryt M, Pamula-Pilat J, Lisowska KM, Grzybowska E, et al. The putative oncogene, CRNDE, is a negative prognostic factor in ovarian cancer patients. Oncotarget. 2015;6(41):43897–43910. DOI:10.18632/oncotarget.6016
   PubMedGoogle Scholar
• Rzepecka IK, Szafron LM, Stys A, Felisiak-Golabek A, Podgorska A, Timorek A, Sobiczewski P, Pienkowska-Grela B, El-Bahrawy M, Kupryjanczyk J. Prognosis of patients with BRCA1-associated ovarian carcinomas depends on TP53 accumulation status in tumor cells. Gynecol Oncol. 2017;144(2):369–376. doi:10.1016/j.ygyno.2016.11.028.
   PubMed Web of Science ®Google Scholar
• Ratajska M, Krygier M, Stukan M, Kuźniacka A, Koczkowska M, Dudziak M, Sniadecki M, Debniak J, Wydra D, Brozek I, et al. Mutational analysis of BRCA1/2 in a group of 134 consecutive ovarian cancer patients. Novel and recurrent BRCA1/2 alterations detected by next generation sequencing. J Appl Genet. 2015 May;56(2):193–198. DOI:10.1007/s13353-014-0254-5.
   PubMed Web of Science ®Google Scholar
• Ganzinelli M, Mariani P, Cattaneo D, Fossati R, Fruscio R, Corso S, Ricci F, Broggini M, Damia G. Expression of DNA repair genes in ovarian cancer samples: biological and clinical considerations. Eur J Cancer. 2011;47(7):1086–1094. doi:10.1016/j.ejca.2010.11.029.
   PubMed Web of Science ®Google Scholar
• van der Groep P, Hoelzel M, Buerger H, Joenje H, de Winter JP, van Diest PJ. Loss of expression of FANCD2 protein in sporadic and hereditary breast cancer. Breast Cancer Res Treat. 2008;107(1):41–47. doi:10.1007/s10549-007-9534-7.
   PubMed Web of Science ®Google Scholar
• Balacescu O, Balacescu L, Tudoran O, Todor N, Rus M, Buiga R, Susman S, Fetica B, Pop L, Maja L, et al. Gene expression profiling reveals activation of the FA/BRCA pathway in advanced squamous cervical cancer with intrinsic resistance and therapy failure. BMC Cancer. 2014;14:246. doi:10.1186/1471-2407-14-246.
   PubMed Web of Science ®Google Scholar
• Ozawa H, Iwatsuki M, Mimori K, Sato T, Johansson F, Toh H, Watanabe M, Mori M. FANCD2 mRNA overexpression is a bona fide indicator of lymph node metastasis in human colorectal cancer. Ann Surg Oncol. 2010;17(9):2341–2348. doi:10.1245/s10434-010-1002-7.
   PubMed Web of Science ®Google Scholar
• Han SS, Tompkins VS, Son DJ, Han S, Yun H, Kamberos NL, Dehoedt CL, Gu C, Holman C, Tricot G, et al. CDKN1A and FANCD2 are potential oncotargets in Burkitt lymphoma and multiple myeloma. Exp Hematol Oncol. 2015;4:9. doi:10.1186/s40164-015-0005-2.
   PubMedGoogle Scholar
• Singh M, Leasure JM, Chronowski C, Geier B, Bondra K, Duan W, Hensley LA, Villalona-Calero M, Li N, Vergis AM, et al. FANCD2 is a potential therapeutic target and biomarker in alveolar rhabdomyosarcoma harboring the PAX3-FOXO1 fusion gene. Clin Cancer Res. 2014;20(14):3884–3895. DOI:10.1158/1078-0432.CCR-13-0556
   PubMed Web of Science ®Google Scholar
• Komatsu H, Masuda T, Iguchi T, Nambara S, Sato K, Hu Q, Hirata H, Ito S, Eguchi H, Sugimachi K, et al. Clinical significance of FANCD2 gene expression and its association with tumor progression in hepatocellular carcinoma. Anticancer Res. 2017;37(3):1083–1090. DOI:10.21873/anticanres.11420
   PubMed Web of Science ®Google Scholar
• Kachnic LA, Li L, Fournier L, Willers H. Fanconi anemia pathway heterogeneity revealed by cisplatin and oxaliplatin treatments. Cancer Lett. 2010;292(1):73–79. doi:10.1016/j.canlet.2009.11.009.
   PubMed Web of Science ®Google Scholar
• Kais Z, Rondinelli B, Holmes A, O’Leary C, Kozono D, D’Andrea AD, Ceccaldi R. FANCD2 maintains fork stability in BRCA1/2-deficient tumors and promotes alternative end-joining DNA repair. Cell Rep. 2016;15(11):2488–2499. doi:10.1016/j.celrep.2016.05.031.
   PubMed Web of Science ®Google Scholar
• Ceccaldi R, Rondinelli B, D’Andrea AD. Repair pathway choices and consequences at the double-strand break. Trends Cell Biol. 2016;26(1):52–64. doi:10.1016/j.tcb.2015.07.009.
   PubMed Web of Science ®Google Scholar
• Hollis RL, Churchman M, Gourley C. 2017. Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancer. Onco Targets Ther. 10:2539–2551. doi:10.2147/OTT.S102569.
   PubMed Web of Science ®Google Scholar
• Telli ML, Timms KM, Reid J, Hennessy B, Mills GB, Jensen KC, Szallasi Z, Barry WT, Winer EP, Tung NM, et al. Homologous Recombination Deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer. Clin Cancer Res. 2016 Aug 1;22(15):3764–3773. doi:10.1158/1078-0432.CCR-15-2477.
   PubMed Web of Science ®Google Scholar
• Nakanishi R, Kitao H, Fujinaka Y, Yamashita N, Iimori M, Tokunaga E, Yamashita N, Morita M, Kakeji Y, Maehara Y. FANCJ expression predicts the response to 5-fluorouracil-based chemotherapy in MLH1-proficient colorectal cancer. Ann Surg Oncol. 2012;19(11):3627–3635. doi:10.1245/s10434-012-2349-8.
   PubMed Web of Science ®Google Scholar
• Eelen G, Vanden Bempt I, Verlinden L, Drijkoningen M, Smeets A, Neven P, Christiaens MR, Marchal K, Bouillon R, Verstuyf A. Expression of the BRCA1-interacting protein Brip1/BACH1/FANCJ is driven by E2F and correlates with human breast cancer malignancy. Oncogene. 2008 Jul;27(30):4233–4241. doi:10.1038/onc.2008.51.
   PubMed Web of Science ®Google Scholar
• Peng M, Litman R, Jin Z, Fong G, Cantor SB. 2006. BACH1 is a DNA repair protein supporting BRCA1 damage response. Oncogene. 25(15):2245–2253. doi:10.1038/sj.onc.1209257.
   PubMed Web of Science ®Google Scholar
• Tu Z, Aird KM, Bitler BG, Nicodemus JP, Beeharry N, Xia B, Yen TJ, Zhang R. Oncogenic RAS regulates BRIP1 expression to induce dissociation of BRCA1 from chromatin, inhibit DNA repair, and promote senescence. Dev Cell. 2011;21(6):1077–1091. doi:10.1016/j.devcel.2011.10.010.
   PubMed Web of Science ®Google Scholar
• Frontini M, Vijayakumar M, Garvin A, Clarke N. A ChIP-chip approach reveals a novel role for transcription factor IRF1 in the DNA damage response. Nucleic Acids Res. 2009;37(4):1073–1085. doi:10.1093/nar/gkn1051.
   PubMed Web of Science ®Google Scholar
• Pontikakis S, Papadaki C, Tzardi M, Trypaki M, Sfakianaki M, Koinis F, Lagoudaki E, Giannikaki L, Kalykaki A, Kontopodis E, et al. Predictive value of ATP7b, BRCA1, BRCA2, PARP1, UIMC1 (RAP80), HOXA9, DAXX, TXN (TRX1), THBS1 (TSP1) and PRR13 (TXR1) genes in patients with epithelial ovarian cancer who received platinum-taxane first-line therapy. Pharmacogenomics J. 2016. doi:10.1038/tpj.2016.63.
   PubMed Web of Science ®Google Scholar
• Dann RB, DeLoia JA, Timms KM, Zorn KK, Potter J, Flake DD2, Lanchbury JS, Krivak TC. BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer. Gynecol Oncol. 2012;125(3):677–682. doi:10.1016/j.ygyno.2012.03.006.
   PubMed Web of Science ®Google Scholar
• Quinn JE, James CR, Stewart GE, Mulligan JM, White P, Chang GK, Mullan PB, Johnston PG, Wilson RH, Harkin DP. BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin Cancer Res. 2007;13(24):7413–7420. doi:10.1158/1078-0432.CCR-07-1083.
   PubMed Web of Science ®Google Scholar
• Weberpals J, Garbuio K, O’Brien A, Clark-Knowles K, Doucette S, Antoniouk O, Goss G, Dimitroulakos J. The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer. Int J Cancer. 2009;124(4):806–815. doi:10.1002/ijc.23987.
   PubMed Web of Science ®Google Scholar
• Taron M, Rosell R, Felip E, Mendez P, Souglakos J, Ronco MS, Queralt C, Majo J, Sanchez JM, Sanchez JJ, et al. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet. 2004;13(20):2443–2449. DOI:10.1093/hmg/ddh260
   PubMed Web of Science ®Google Scholar
• Rosell R, Skrzypski M, Jassem E, Taron M, Bartolucci R, Sanchez JJ, Mendez P, Chaib I, Perez-Roca L, Szymanowska A, et al. BRCA1: a novel prognostic factor in resected non-small-cell lung cancer. PLoS One. 2007;2(11):e1129. DOI:10.1371/journal.pone.0001129
   PubMed Web of Science ®Google Scholar
• Gao Y, Zhu J, Zhang X, Wu Q, Jiang S, Liu Y, Hu Z, Liu B, Chen XBRCA1 mRNA expression as a predictive and prognostic marker in advanced esophageal squamous cell carcinoma treated with cisplatin- or docetaxel-based chemotherapy/chemoradiotherapy. PLoS One. 2013;8(1):e52589. doi:10.1371/journal.pone.0052589.
   PubMed Web of Science ®Google Scholar
• Egawa C, Miyoshi Y, Takamura Y, Taguchi T, Tamaki Y, Noguchi S. Decreased expression of BRCA2 mRNA predicts favorable response to docetaxel in breast cancer. Int J Cancer. 2001;95(4):255–259.
   PubMed Web of Science ®Google Scholar
• Lim SL, Smith P, Syed N, Coens C, Wong H, van der Burg M, Szlosarek P, Crook T, Green JA. Promoter hypermethylation of FANCF and outcome in advanced ovarian cancer. Br J Cancer. 2008;98(8):1452–1456. doi:10.1038/sj.bjc.6604325.
   PubMed Web of Science ®Google Scholar
• Jaber S, Toufektchan E, Lejour V, Bardot B, Toledo F. p53 downregulates the Fanconi anaemia DNA repair pathway. Nat Commun. 2016;7:11091. doi:10.1038/ncomms11091.
   PubMed Web of Science ®Google Scholar
• Wysham WZ, Mhawech-Fauceglia P, Li H, Hays L, Syriac S, Skrepnik T, Wright J, Pande N, Hoatlin M, Pejovic T. BRCAness profile of sporadic ovarian cancer predicts disease recurrence. PLoS One. 2012;7(1):e30042. doi:10.1371/journal.pone.0030042.
   PubMed Web of Science ®Google Scholar
• Horiuchi A, Wang C, Kikuchi N, Osada R, Nikaido T, Konishi I. BRCA1 expression is an important biomarker for chemosensitivity: suppression of BRCA1 increases the apoptosis via up-regulation of p53 and p21 during cisplatin treatment in ovarian cancer cells. Biomark Insights. 2007;1:49–59.
   PubMedGoogle Scholar
• Wu K, Jiang SW, Couch FJ. p53 mediates repression of the BRCA2 promoter and down-regulation of BRCA2 mRNA and protein levels in response to DNA damage. J Biol Chem. 2003;278(18):15652–15660. doi:10.1074/jbc.M211297200.
   PubMed Web of Science ®Google Scholar
• Gayther SA, Mangion J, Russell P, Seal S, Barfoot R, Ponder BA, Stratton MR, Easton D. Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat Genet. 1997;15(1):103–105. doi:10.1038/ng0197-103.
   PubMed Web of Science ®Google Scholar
• Rebbeck TR, Mitra N, Wan F, Sinilnikova OM, Healey S, McGuffog L, Mazoyer S, Chenevix-Trench G, Easton DF, Antoniou AC, et al. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA. 2015;313(13):1347–1361. DOI:10.1001/jama.2014.5985
   PubMed Web of Science ®Google Scholar
• Kluska A, Balabas A, Paziewska A, Kulecka M, Nowakowska D, Mikula M, Ostrowski J. New recurrent BRCA1/2 mutations in Polish patients with familial breast/ovarian cancer detected by next generation sequencing. BMC Med Genomics. 2015;8:19. doi:10.1186/s12920-015-0092-2.
   PubMed Web of Science ®Google Scholar
• Wojcik P, Jasiowka M, Strycharz E, Sobol M, Hodorowicz-Zaniewska D, Skotnicki P, Byrski T, Blecharz P, Marczyk E, Cedrych I, et al. Recurrent mutations of BRCA1, BRCA2 and PALB2 in the population of breast and ovarian cancer patients in Southern Poland. Hered Cancer Clin Pract. 2016;14:5. doi:10.1186/s13053-016-0046-5.
   PubMed Web of Science ®Google Scholar
• Kowalik A, Siołek M, Kopczyński J, Krawiec K, Kalisz J, Zięba S, Kozak-Klonowska B, Wypiórkiewicz E, Furmańczyk J, Nowak-Ozimek E, et al. BRCA1 founder mutations and beyond in the polish population: a single-institution BRCA1/2 next-generation sequencing study. PLoS One. 2018;13(7):e0201086. DOI:10.1371/journal.pone.0201086
   PubMed Web of Science ®Google Scholar
• Rzepecka IK, Szafron L, Stys A, Bujko M, Plisiecka-Halasa J, Madry R, Osuch B, Markowska J, Bidzinski M, Kupryjanczyk J. High frequency of allelic loss at the BRCA1 locus in ovarian cancers: clinicopathologic and molecular associations. Cancer Genet. 2012;205(3):94–100. doi:10.1016/j.cancergen.2011.12.005.
   PubMed Web of Science ®Google Scholar
• Dansonka-Mieszkowska A, Kluska A, Moes J, Dabrowska M, Nowakowska D, Niwinska A, Derlatka P, Cendrowski K, Kupryjanczyk J. A novel germline PALB2 deletion in polish breast and ovarian cancer patients. BMC Med Genet. 2010;11:20. doi:10.1186/1471-2350-11-20.
   PubMed Web of Science ®Google Scholar
• Karakasis K, Burnier JV, Bowering V, Oza AM, Lheureux S. Ovarian cancer and BRCA1/2 testing: opportunities to improve clinical care and diseaseprevention. Front Oncol. 2016;6:119. doi:10.3389/fonc.2016.00119.
   PubMed Web of Science ®Google Scholar
• Ledermann JA, Drew Y, Kristeleit RS. Homologous recombination deficiency and ovarian cancer. Eur J Cancer. 2016;60:49–58. doi:10.1016/j.ejca.2016.03.005.
   PubMed Web of Science ®Google Scholar
• Kupryjanczyk J, Kraszewska E, Ziolkowska-Seta I, Madry R, Timorek A, Markowska J, Stelmachow J, Bidzinski M. TP53 status and taxane-platinum versus platinum-based therapy in ovarian cancer patients: a non-randomized retrospective study. BMC Cancer. 2008;8:27. doi:10.1186/1471-2407-8-27.
   PubMed Web of Science ®Google Scholar
• Peterson F, Kolstad P, Ludwig H, Ulfelder H. Annual report on the results of treatment in gynecological cancer Vol. 20. Stockholm: International Federation of Gynecology and Obstetrics; 1988.
   Google Scholar
• Tavassoli FA, Devilee P. WHO classification of tumors. Pathology and genetics of tumors of breast and female genital organs. Lyon (France): IARC Press; 2003.
   Google Scholar
• Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47(1):207–214.
   PubMed Web of Science ®Google Scholar
• Christian MC, Trimble EL. Salvage chemotherapy for epithelial ovarian carcinoma. Gynecol Oncol. 1994;55(3 Pt 2):S143–50. doi:10.1006/gyno.1994.1354.
   PubMed Web of Science ®Google Scholar
• Wagner T, Stoppa-Lyonnet D, Fleischmann E, Muhr D, Pagès S, Sandberg T, Caux V, Moeslinger R, Langbauer G, Borg A, et al. Denaturing high-performance liquid chromatography detects reliably BRCA1 and BRCA2 mutations. Genomics. 1999;62(3):369–376. doi:10.1006/geno.1999.6026.
   PubMed Web of Science ®Google Scholar
• Lewis AG, Flanagan J, Marsh A, Pupo GM, Mann G, Spurdle AB, Lindeman GJ, Visvader JE, Brown MA, Chenevix-Trench G, et al. Mutation analysis of FANCD2, BRIP1/BACH1, LMO4 and SFN in familial breast cancer. Breast Cancer Res. 2005;7(6):R1005–R16. Epub 2005 Oct 21. doi:10.1186/bcr1336.
   PubMed Web of Science ®Google Scholar
• Dansonka-Mieszkowska A, Ludwig AH, Kraszewska E, Kupryjańczyk J. Geographical variations in TP53 mutational spectrum in ovarian carcinomas. Ann Hum Genet. 2006 Sep;70(Pt 5):594–604. doi:10.1111/j.1469-1809.2006.00257.x.
   PubMedGoogle Scholar